Product logins

Find logins to all Clarivate products below.


Chronic Obstructive Pulmonary Disease – Epidemiology – Middle East & Africa

Clarivate Epidemiology’s coverage of chronic obstructive pulmonary disease (COPD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of COPD for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s COPD forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with COPD?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of COPD?
  • Of all people with COPD, how many in each country have been formally diagnosed?
  • Of all people diagnosed with COPD, how many in each country in the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of COPD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 24 COPD patient populations, including the following:

  • Total prevalent cases of COPD.
  • Total prevalent cases of GOLD-defined COPD.
  • Prevalent cases of spirometric-negative COPD.
  • Diagnosed prevalent cases of GOLD-defined COPD.
  • Diagnosed prevalent cases of mild to moderate COPD.
  • Diagnosed prevalent cases of severe to very severe COPD.
  • Diagnosed prevalent cases of COPD with comorbid lifetime asthma.
  • Prevalent cases of eosinophilic COPD.
  • … and many more (details available on request).

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Sarcoidosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Sarcoidosis (US)
Sarcoidosis is a multisystem inflammatory disorder marked by granuloma formation, most often affecting the lungs, lymph nodes, skin, eyes, and heart. Corticosteroids such as prednisone are the…
Report
Asthma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…
Report
Biosimilars – Forecast – Respiratory
In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast…
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…